Exubrion Therapeutics
Board of Directors

A seasoned and highly-experienced team

At Exubrion, our Board of Directors bring a broad range of experience across numerous therapeutic and business areas to our team.

Mr. Dennis Steadman

Mr. Dennis Steadman

Chairman of the Board
Exubrion Therapeutics™

Mr. Immanuel Thangaraj

Mr. Immanuel Thangaraj

Managing Director
Essex Woodlands Health Ventures, Inc.

Dr. Rob Readnour

Dr. Rob Readnour

Managing Director
Mountain Group Partners

Dr. Mark Pykett

Dr. Mark Pykett

Chief Scientific Officer
PTC Therapeutics

Ms. Julia Stephanus

Ms. Julia Stephanus

Chief Commercial Officer
Aratana Therapeutics, Inc.

Peter

Mr. Peter Selover

Chief Executive Officer
Exubrion Therapeutics™

Synovetin OA™ delivers sustained OA pain relief.1

Synovetin OA™ provides targeted, non-systemic therapy.2

References:

  1. Data on file, Exubrion Therapeutics.
  2. Donecker JM, Fox SM. Safety and effectiveness of Synovetin OA™: Results of three randomized trials evaluating treatment of naturally occurring canine elbow osteoarthritis. Exubrion Therapeutics, July 2019.